home / stock / mgtx / mgtx news

MGTX News and Press, MeiraGTx Holdings plc From 08/24/20

Stock Information
Company Name: MeiraGTx Holdings plc
Stock Symbol: MGTX
Market: NASDAQ
Website: meiragtx.com
Menu
MGTX MGTX Quote MGTX Short MGTX News MGTX Articles MGTX Message Board
Get MGTX Alerts

News, Short Squeeze, Breakout and More Instantly...
MGTX - MeiraGTx Is A Buy With Multiple Near-Term Catalysts As The Stock Is Weighed Down By Negative Sentiment

Company Overview MeiraGTx ( MGTX ) is a clinical-stage gene therapy company targeting serious conditions with no existing curative options or even acceptable therapeutic approaches. It has four clinical-stage programs for ocular conditions, one for Parkinson's disease, and one for radiatio...
MGTX - MeiraGTx EPS misses by $0.14

MeiraGTx (NASDAQ: MGTX ) : Q2 GAAP EPS of -$0.69 misses by $0.14 . More news on: MeiraGTx Holdings plc, Earnings news and commentary, Healthcare stocks news, Read more ...

MGTX - MeiraGTx Reports Second Quarter 2020 Financial Results

- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical trial - Expands manufacturing capabilities with new facilities in Ireland LONDON and NEW YORK, Aug. 06, 2020 (G...

MGTX - MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer

LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin, M.D. as chief medical officer (CMO). A clinical immunologist by tr...
MGTX - MeiraGTx Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

MeiraGTx reports encouraging data for ocular gene therapy MeiraGTx ( MGTX ) announced initial data from its ongoing clinical trial of AAV-RPGR, for treating patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. The dose escalation phase ...

MGTX - NVAX, ERIC among premarket gainers

RumbleON (NASDAQ: RMBL ) +117%  on pilot program with CarGurus. More news on: RumbleON, Inc., Verona Pharma plc, Applied DNA Sciences, Inc., Stocks on the move, , Read more ...

MGTX - J&J gene therapy shows encouraging action in vision loss disorder

Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceutical Companies reports positive six-month data from a Phase 1/2 clinical trial evaluating gene therapy AAV-RPGR in patients with X-linked retinitis pigmentosa , a group of inherited retinal disorders characterized by progressiv...
MGTX - MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients

• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting   • Significant improvements demonstrated after treatment in Phase 1/2 clinical trial   • Based on encouraging safety and efficacy profile,...

MGTX - MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders

LONDON and NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that its 2020 Annual General Meeting of Shareholders scheduled for Tuesday, June 2, 2020 at 10:00 a.m. ET,...

MGTX - MeiraGTx EPS in-line

MeiraGTx (NASDAQ: MGTX ): Q1 GAAP EPS of -$0.43 in-line. More news on: MeiraGTx Holdings plc, Earnings news and commentary, Healthcare stocks news, Read more ...

Previous 10 Next 10